avapro has been researched along with Brain Vascular Disorders in 2 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension." | 8.31 | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients. ( Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG, 2023) |
| " We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension." | 4.31 | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients. ( Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG, 2023) |
| "Hypertension is an important risk factor for cardiovascular disease (CVD), particularly in patients with comorbid obesity, diabetes, metabolic disease, or end-organ damage." | 2.44 | The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy. ( Ruilope, LM; Segura, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoo, YG | 1 |
| Lim, MJ | 1 |
| Kim, JS | 1 |
| Jeong, HE | 1 |
| Ko, H | 1 |
| Shin, JY | 1 |
| Ruilope, LM | 1 |
| Segura, J | 1 |
1 review available for avapro and Brain Vascular Disorders
| Article | Year |
|---|---|
The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiovascular Diseases; Causality; Cer | 2008 |
1 other study available for avapro and Brain Vascular Disorders
| Article | Year |
|---|---|
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2023 |